John Dengler, MD
Sleep Medicine · Johnson City, TNNPI 1396790085
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 1,058 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 7.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $4,021 and has fallen 99.1% since, to $35 in 2025. Among sleep medicine clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,058 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Novartis$1K
- AbbVie$1K
- Biogen$1K
- Neurelis, Inc.$941
- AstraZeneca$852
- plus $12K from 54 others
Across 56 payments — averaging $9464.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$309K
- Genentech, Inc.$199K
- UCB SA$22K
- Pfizer$12
What the payments were for
- Speaking & faculty fees$590%
- Food & beverage$19,12599%
- Education$2181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,402 in reported general payments places this provider in the 90th percentile of 41 sleep medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 51 | $315,937 |
| MayzentSiponimod | 27 | $274,002 |
| WakixPitolisant Hcl | 12 | $213,041 |
| XembifyImmune Globulin,gamma(Igg)klhw | 13 | $189,002 |
| EpidiolexCannabidiol (Cbd) | 41 | $154,959 |
| Rufinamide | 72 | $105,014 |
| AptiomEslicarbazepine Acetate | 68 | $103,870 |
| NuedextaDextromethorphan Hbr/Quinidine | 50 | $79,562 |
| BriviactBrivaracetam | 48 | $71,696 |
| GlatopaGlatiramer Acetate | 15 | $40,320 |
| Nurtec OdtRimegepant Sulfate | 24 | $37,106 |
| FycompaPerampanel | 21 | $25,957 |
| Lacosamide | 281 | $25,891 |
| NamzaricMemantine Hcl/Donepezil Hcl | 21 | $21,142 |
| TopamaxTopiramate | 14 | $18,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $386 | $315,93751 claims |
| NovartisMayzent | $1,308 | $274,00227 claims |
| Harmony Biosciences LLCWakix | $260 | $213,04112 claims |
| Grifols USA, LLCXembify | $140 | $189,00213 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $162 | $103,87068 claims |
| UCB, Inc.Briviact, Vimpat | $1,530 | $89,66262 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $312 | $79,56250 claims |
| PfizerNurtec Odt, Dilantin, Dilantin | $434 | $45,80970 claims |
| SandozGlatopa | $54 | $40,32015 claims |
| AbbVieNamzaric, Ubrelvy | $1,152 | $32,69832 claims |
| Eisai Inc.Fycompa | $734 | $25,95721 claims |
| Neurelis, Inc.Valtoco | $941 | $17,11315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 sleep medicine providers in Tennessee.
Other sleep medicine in Johnson City
- Melissa KhalilJohnson City$4K
- Bijoy JohnBrentwood$38K
- Kelly CardenNashville$24K
- Martha HagamanFranklin$20K
- Prashant JamesKnoxville$11K
- Kevin MartinolichKnoxville$9K
- Merrill WiseMemphis$7K
- Christopher NolteKnoxville$7K
- Nancy LambCordova$5K
- James AndrewsMemphis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.